Effects of Sustamine(TM) on Cycling Time Trial Performance
NCT ID: NCT01623947
Last Updated: 2013-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
14 participants
INTERVENTIONAL
2012-06-30
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Astaxanthin Properties on Anti-fatigue
NCT06593535
Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance
NCT01710761
The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.
NCT06274385
Impact of Nutritional Supplementation on Aerobic Performance and Fatigue
NCT02134756
The Effect of a Caffeine Blend on Reaction Time, Mental Performance and Focus in Athletic Males
NCT03019523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo Beverage
1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
2.8 g Sustamine
2.8 g Sustamine Beverage
1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
19.6 g Sustamine
19.6 g Sustamine Beverage
1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo Beverage
1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
2.8 g Sustamine Beverage
1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
19.6 g Sustamine Beverage
1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male (VO2max \>= 55 ml/kg/min) or Female (VO2max \>= 45 ml/kg/min)
* Healthy
* Blood pressure below 140/90
* Non-smoker
Exclusion Criteria
* Inconsistent regular medications
* Consumption performance-enhancing substances
* Type I or Type II diabetes
* Renal, hepatic or cardiac disease Current infectious disease
20 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyowa Hakko Bio Co., Ltd.
INDUSTRY
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John L. Ivy, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Texas at Austin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Texas at Austin
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-03-0043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.